







































The effect of wide resection margin in patients
with intrahepatic cholangiocarcinoma
A single-center experience
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Abstract
Introduction: Prognosis of intrahepatic cholangiocarcinoma (ICC) remained poor despite the multitude advancement of medical
care. Resection margin status is one of the few modifiable factors that a surgeon could possibly manipulate to alter the disease
outcome. However, the significance of margin status and margin width is still controversial. This study serves to further elucidate the
role of them.
Method: This is a retrospective cohort from the Queen Mary Hospital, The University of Hong Kong. Consecutive patients
diagnosed to have ICC and with surgical resection performed in curative intent were retrieved, while patients with
cholangiohepatocellular carcinoma, Klaskin tumor, tumor of extrahepatic bile duct, and uncertain tumor pathology were excluded.
Results: From 1991 to 2013, there were 107 patients underwent hepatectomy for ICC. Gender predilection was not observed with
58 males and 49 females, median age of the patients was 61. The median tumor size was 6cm and most of them (43%) were
moderately differentiated adenocarcinoma. Clear resection margin were achieved in 95 patients (88.8%) and the median margin
width was 0.5cm. The hospital length of stay and operative mortality were 11 days and 3%, respectively. The disease-free survival
and overall survival were 17.5 and 25.1 months, respectively. Multivariate analysis showed that margin width was an independent
factor associated with disease-free survival (P=0.015, 95% confidence interval [CI] 0.4–0.9). Subgroup analysis in patients with
solitary tumor showed that margin width is an independent factor affecting overall survival (P=0.048; odds ratio: 0.577; 95% CI:
0.334–0.996). Discriminant analysis showed that the overall survival increased from 36 to 185 months when margin width was>0.9
cm (P=0.025) in patients with solitary tumor.
Conclusion:Aggressive resection to achieve resection margin of at least 1cmmaximizes chance of cure in patients with early ICC.
Abbreviations: CEA = carcinoembryonic antigen, CT = computed tomography, ICC = intrahepatic cholangiocarcinoma, ICG =
indocyanine green, IOUS = intraoperative ultrasonography, R0 = clear resection margin > 1mm, R1 = clear resection margin < 1
mm, R2 = margin involved, RPC = recurrent pyogenic cholangitis, TNM = tumor-node-metastasis, UICC = union for international
cancer control.
Keywords: hepatectomy, ICC, liver resection, long-term outcome, survival analysis
1. Introduction
Cholangiocarcinoma is an uncommon malignancy, which
accounts for <2% of all human cancers.[1] While intrahepatic
cholangiocarcinoma (ICC) contributes to around 20% to 25% of
all cholangiocarcinomas, it ranks the second most common
primary cancer of the liver following hepatocellular carcinoma.[2]
Pathologically, it can be classified into 3 types, namely, mass-
forming, peri-ductal infiltrative, and intraductal growth.[3]
Unlike the least prevalent intraductal growth type, ICC is
generally associated with poor prognosis; this is partly due to its
aggressive tumor biology[4] and late presentation secondary to a
relatively asymptomatic intrahepatic tumor.[5–7] Only 10% to
20% of the ICCs are deemed resectable at the time of
presentation[8] and the median survival ranges from 6 to 9
months for patients with unresectable disease.[9–11]
Surgical resection remains the only hope of cure in patients
with ICC, and the 5-year survival after surgical resection is
around 25% to 35%.[12] Despite the multitude advancement in
various aspects of hepatic operation, there has been little
breakthrough concerning the survival of patients with ICC in
the last decade.[7,13] Studies had looked into the factors that
might potentially influence treatment outcomes, these included
tumor size, tumor multifocality, vascular invasion, lymph node
status, and resection margin status.[5–7,14–23] Among all of these
factors, only resection margin and the width of clear resection
marginwere technically modifiable by the operating surgeon. The
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practice of aggressive hepatectomy to strive for a wider resection
margin in order to improve survival has been controversial. The
findings of a recently published multicenter study by the French
Association Francophone de Chirurgie–Intrahepatic Cholangio-
carcinoma (AFC-IHCC)-2009 Study Group advocated a “wider
the better” concept in selected group of patients.[22] The
generalizability of this result to oriental patients has yet to be
confirmed, furthermore, a number of heterogeneities exemplified
by multicenter study could be mitigated by a well-designed,
single-center series with reasonable sample size. Therefore, we
perform this study to the share our experience in managing ICC
and to further explore the association between resection margin
and patient survivals.
2. Patients and methods
2.1. Patient selection
Patients diagnosed to have ICC and with subsequent hepatecto-
my performed with curative intent in the period between 1991
and 2013 were extracted from a prospectively maintained
database in QueenMary Hospital, The University of Hong Kong
medical center. Patients with cholangiohepatocellular carcinoma,
Klaskin tumor, and cholangiocarcinoma arising from extrahe-
patic biliary tract or suspected metastatic adenocarcinoma of
liver were excluded from analysis. All patients included in our
series had at least macroscopic (R0 or R1) curative resection.
Diagnosis was confirmed by dedicated hepatobiliary patholo-
gists. ICC by definition should arise from the periphery of biliary
system, that is, second-order bile duct branching onward. In
addition to standard microscopy and staining, immunohisto-
chemical tests including cytokeratin-7, cytokeratin-20, and
thyroid transcription factor-1 would be performed whenever
necessary.
2.2. Preoperative assessments
Patients with working diagnosis of ICCwould undergo a series of
biochemical and radiological assessments before embarking on
hepatectomy. Complete blood count, liver, renal function tests,
and clotting profile were checked as routine. Hepatitis serology,
baseline level of carcinoembryonic antigen (CEA), and Child-
Pugh scoring were documented. All patients would undergo
indocyanine green (ICG) clearance test, ICG retention of 18%
and 22% at 15 min after injection were regarded as the cut-off
level for major and minor hepatic resection, respectively.
Radiologically, a contrasted computed tomography (CT) with
or without 18-F 2-fluoro-2-deoxy-D-glucose positron emitted
tomography was performed to define local anatomy and presence
of systemic involvement. A CT volumetric study would be
required for patients requiring major hepatectomy (resection of 3
or more Couinaud segments). The minimum ratio of future liver
remnant volume versus estimated standard liver volume was
30% for noncirrhotic livers.[24,25] In case of marginal liver
volume, percutaneous image guided portal vein embolization or
associating liver partition with portal vein ligation for staged
hepatectomy could be considered on individual basis in a
multidisciplinary meeting.
2.3. Definitions
The nomenclature of liver anatomy and resection follows
that of the International Hepato-Pancreato-Biliary Association
(Brisbane 2000) consensus statement.[26] Hospital mortality was
defined as any mortality happened in the first 30 days after the
operation and operative mortality was defined as any mortality
happened within the first 90 days after operation. Clear resection
margin (R0) was defined as the distance between the non-
tumorous tissue and cancer cell >1mm. R1 resection referred to
resection margin touching inked tumor, while R2 resection
means gross residual disease, which was an exclusion criteria in
this study. Postoperative complications were classified according
to Clavien-Dindo description.[27] All cancer staging follows that
of the Union for International Cancer Control/Tumor-Node-
Metastasis (TNM) 7th edition.[28]
2.4. Surgical techniques
The technical details of hepatectomy in our center had been
described in another report.[24] Operation started with either
midline incision, right subcostal with midline extension, or
bilateral subcostal with midline extension depending on the
location of tumor and anticipated magnitude of hepatectomy.
Routine intraoperative ultrasonography (IOUS) was performed
to look for any vascular invasion; presence of tumor in the
contralateral lobe precludes curative resection. Transection
plane was defined by color demarcation after temporary inflow
occlusion and IOUS vascular mapping. Liver transection was
then started with the use of Cavitron ultrasonic dissector in
either conventional or anterior approach depending on the
location and size of tumor. Frozen section for bile duct resection
margin was not routinely done unless tumor extension was
suspected. Vasculobiliary resection and reconstruction was
contemplated whenever necessary to achieve R0 resection.
Caudate lobe resection was not routinely included unless the
tumor was centrally locating. Central venous pressure was kept
at around 5 mm Hg during parenchymal transection.
Monopolar, bipolar diathermy, argon beam coagulation, metal
clips, fine suture placation, and various commercial hemostatic
products would be applied for hemostasis. Intermittent Pringle
maneuver or total vascular exclusion was applied only when
excessive bleeding encountered. Bile leakage was checked by
cannulation of cystic duct with a 5-french Argyle catheter
followed by injection of methylene blue solution. Drain was not
placed unless collection was anticipated. Patient could be
discharged home around 1 to 2 weeks depending on individual
progress of recovery.
2.5. Follow-up and surveillance
All patients were followed up at outpatient clinic within 2 weeks
after discharge home and then every quarter-yearly for the first
year and half-yearly for the second year onward according to
individual progress. Routine blood tests including liver function
and CEA were checked before every follow-up and cross-
sectional imaging was arranged every half-yearly or earlier
whenever necessary. Disease recurrence was declared if contrast
CT shows features of local recurrence or distant metastasis.
2.6. Statistics
Continuous variables were described as median with range
included in bracket. Categorical variables were analyzed using
Chi-squared test or Fisher exact test where appropriate.
Parametric variables were analyzed using Mann–Whitney U test
or t test where appropriate. Disease-free and overall survivals
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were calculated from the day of discharge to the day of disease
recurrence or census, that is, death or last follow up, using
Kaplan–Meier method. Survivals between groups were compared
using Log-rank test. Variables associated with survival with P<
0.1 in univariate analysis were put into multivariate analysis in
order to identify the independent factors. P value of <0.05 was
considered statistically significant. Discriminant analyses were
performed to identify cut-off values of margin width that affect
survival. Statistical Product and Service Solutions version 20 was
used for all statistical analysis.
2.7. Ethics and declarations
This study does not require ethics board review according to local
guidelines. All patient identities and clinical information were
kept confidential. The authors declare no known benefit from this
article.
3. Results
From 1991 to 2013, there were 107 consecutive patients received
intended curative hepatectomy for ICC and were included for
analysis. Gender predilection was not observed, with male
patients being slightly more common than their female counter-
parts (58 males and 49 females). The median age was 61 (25–79)
years old and the follow-up time was 21.4 months (0.2–276.3).
Hepatitis B carrier state was confirmed in 33.6% of our patients.
Pathological changes compatible with of underlying recurrent
pyogenic cholangitis (RPC) was noted in 17 patients (15.9%).
The hospital length of stay and hospital mortality of our series
were 11 days and 3%, respectively (Table 1). The 5-year disease-
free and overall survivals of this series were 39% and 36.7%,
respectively. There were 7 (6.5%) patients died within 90 days of
operation. Postoperative complications occurred in 34 patients
(31.8%), with grade IIIA, IIIB, IV, and V complication occurred
in 14, 3, 2, and 8 patients, respectively.
Majority of our patients required major hepatectomy (defined
asmore than 3 segmental resection) for tumor resection, and right
trisectionectomy was the most commonly performed surgical
procedure (Table 2). Added procedure was required in 21
patients (19.5%), bile duct resection was performed in 15
patients, other 5 had portal vein, inferior vena cava, or hepatic
artery resection and reconstruction, 1 patient had intraoperative
radiofrequency ablation of tumor performed.
The median size of the primary tumor was 6cm (1–17cm) and
most of the tumors were moderately differentiated adenocarci-
noma. For the TNM staging, there were 43%, 22%, 23%, and
12% of the patients belonged to stage I, II, III, and IV,
respectively, and the overall survival correlate well with TNM
staging (Fig. 1). All patients had macroscopic clear resection with
only 12 patients had microscopic margin involvement according
to definition. R0 resection was achieved in 95 patients (88.8%),
and the rate of R0 resection seemed not to be affected by the
operation time, magnitude of hepatectomy, need of additional
procedure, tumor size, presence of vascular invasion, and TNM
staging (Table 3). The median margin width was 0.5cm. The
median time to first recurrence was 9.7 months (0.53–160.6).
Tumor recurrence documented in 58% in our series, and most of
them had both intrahepatic and extrahepatic recurrences
(22.4%). A smaller percentage of patients had intrahepatic
recurrence only (15%). The disease-free and overall survivals
were 17.5 months (0.5–276.3) and 25.1 months (0.2–276.3),
Table 1
Clinicopathological characteristics of 107 patients with ICC.
Basic characteristics n=107
Median age, y (range) 61 (25–79)
Male sex 58 (54.2%)
Body weight, kg 55.6 (36–85.6)
Body height, cm 162 (142–185)
Smoker 36 (33.6%)
Drinker 26 (24.5%)





Hepatitis B carrier 36 (33.6%)
Preoperative biochemistry
Hemoglobin, g/dL 12.8 (8.2–16.7)
White cell count, 109/L 6.9 (1.3–31.8)
Platelet count, 109/L 206 (47–527)
Creatinine, mmol/L 77 (37–167)
Albumin, g/L 41 (25–51)
Bilirubin, mmol/L 10 (3–94)
ALP, U/L 99 (38–830)
Prothrombin time, s 11.6 (9.6–17.8)
CEA 2.4 (0.3–151)
Follow-up time, mo 24.38 (3.19–276.27)
Hospital stay, d 11 (4–281)
Blood transfusion rate 27 (25.2%)
Median blood loss, L (range) 0.9 (0.1–26.6)
30-d mortality, % 3 (2.8%)
90-d mortality, % 7 (6.5%)
Coexisting RPC 17 (15.9%)
Size of primary tumor, cm 6 (1–17)
Tumor differentiation
Well differentiated 11 (10.3%)
Moderately differentiated 46 (43%)
Poorly differentiated 26 (24.3%)
Macrovascular invasion, yes (%) 13 (12.1%)






CEA = carcinoembryonic antigen, ICC = intrahepatic cholangiocarcinoma, RPC = recurrent pyogenic
cholangitis, TNM = tumor-node-metastasis, UICC7 = Union for International Cancer Control, 7th
edition.
Table 2
Frequency of various surgical procedures performed.
Details of hepatectomy N (%)
Right hepatectomy 13 (12.1)
Extended right hepatectomy 5 (4.7)
Left hepatectomy 11 (10.3)
Extended left hepatectomy 7 (6.5)
Left lateral sectionectomy 10 (9.3)
Right trisectionectomy 16 (15)






Additional procedures† 21 (19.5)
∗
Others include central bisectionectomy, central bisectionectomy + caudate resection, isolated
segment + caudate lobe resection.
† Additional procedures include 15 bile duct resection, 4 portal vein resection and reconstruction, 1
hepatic artery or inferior vena cava resection and reconstruction, and 1 radiofrequency ablation.
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respectively. Univariate analysis was performed for a number of
clinicopathological factors (Table 4) and there were 6 factors
identified to be associated with disease-free survival of the
patients, namely primary tumor size (P=0.026), postoperative
surgical complication (P=0.006), multifocality (P<0.0001),
width of resection margin (P=0.015), and TNM staging (P=
0.015). After multivariate analysis, only postoperative surgical
complication (P=0.032, 95% confidence interval [CI]: 1.1–3.2),
TNM staging (P=0.001), and width of resection margin (P=
0.015, 95% CI: 0.4–0.9) stand out as the independent factors
affecting disease-free survival. In order to find out the minimal
resection margin required to obtain an improved result, a
discriminant analysis was performed and it was found that the
disease-free survival increased from 14.1 to 86 months when
width of resection margin is more than 1cm (P=0.008) (Fig. 2).
Concerning the overall survival, 6 factors were shown to be
associated after univariate analysis, including preoperative
intraoperative blood loss (P=0.014), surgical complication
(P<0.0001), multifocality (P<0.0001), width of resection
margin (P=0.014), and TNM staging (P<0.0001). Although
multivariate analysis showed that only postoperative complica-
tion (P=0.0004, odds ratio [OR]: 2.87; 95% CI: 1.649–4), and
TNM staging (P<0.05) were the 2 independent factors affecting
overall survival (Table 5). Subgroup analysis was performed in
patients with solitary tumor and showed that width of resection
margin is an independent factor affecting overall survival (P=
0.048; OR: 0.577; 95% CI: 0.334–0.996) (Table 6). Discrimi-
nant analysis was performed in this subgroup and found that if
resection margin more than 0.9cm, the median survival would be
increased from 35.7 to 184.6 months (P=0.025) (Fig. 3).
4. Discussion
To our knowledge, this is the largest single-center retrospective
series focusing on oncological outcome of resectable ICC. In this
series, the 5-year overall survival for patients who received
Figure 1. Stage-specific overall survival of patient with intrahepatic cholangiocarcinoma after operation.
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operation of curative intent was 36.7% and this figure was
comparable to other major series in the literatures.[21,29–31] Some
known risk factors associated with ICC included hepatitis B and
C carrier state, cirrhotic liver disease, Opisthorchis viverrini and
Clonorchis sinensis infestation, RPC, and choledochal cyst
present only in about 10% of our patients. Given the fact that
symptoms were uncommon in early stage of disease, biochemical
and radiological surveillance should be performed on regular
basis in patients who possess these risk factors.
Microscopic clear margin status has been regarded as the
ultimate objective in resection of ICC and it had been shown by a
number of studies that R0 resection was associated with improved
survival[5,6,14–18,20–22,32] while a few suggested the contrary.[7,33,34]
Despite we were unable to demonstrate R0 resection has
oncological benefit over R1 resection, probably as a result of
small case number in the R1 group (95 vs 12 in R0 and R1,
respectively), the authorswere inclined to support thatR0 resection
margin should be achieved as much as possible for an adequate
oncological clearance.Toaccount forover10%R1resection rate in
this series, regardless of the relatively “small tumor size” (median
tumor size was 6cm), the reasons were 3-fold; anatomically, some
of the tumors situated at strategic area rendering on-bloc resection
too risky to be performed, hence a vascular or bile ductmarginwas
relentlessly left behind; morphologically, irregular tumor border of
infiltrative or mixed type ICC could lead to false sense of margin
adequacy from both tactile and IOUS examination; lastly, skipped
lesions or small satellite nodule could still be missed with the finest
loupe or ultrasound machine. The last 2 reasons set the stage for
advocating a more aggressive resection margin especially for
seemingly solitary tumor and node negative disease. Concerning
adequate width of resection margin, few literatures addressed this
controversial issue directly[35–38] and we demonstrated that the
wider the width of resection margin, the longer is the disease-free
survival and overall survival in selected group of patients. Belghiti
et al[38] reviewed 30 patients who had ICC and hepatectomy for
curative intent. In that article they concluded that resection margin
hadno impacton survival.However, thatfinding couldnotbeover-
generalized as all of their patients were TMN stage III or above and
with around 40%of themhad terminal disease, that is, TMN stage
IV; therefore, the beneficial effect of wide resection margin might
well bemaskedby the“too far gone”advanceddisease status. From
our multivariate analysis, we found that resection margin width
was an independent factor for disease-free survival and discrimi-
nant analysis performed showed that a cut-off width of resection
margin 1cm is associatedwith improved disease-free survival. This
finding serves 2 purposes; on one hand, this should be the minimal
margin width that the operating surgeon should aim for when they
are operating on patient with apparent early disease. On the other
hand, ultimate margin with as per pathological assessment helps to
prognosticate disease outcome and to select high-risk group for
adjuvant therapies. Though we could not establish the similar
relationship with overall survival due to a number of reasons, that
is, small case number and disease-unrelated mortality, our findings
concurred with the study published by Farges et al[22] who
suggested wide resection margin in a similar group of patients. All
these results suggest that, aggressive surgery achieving a wide
resectionmargin could improve survival in patients with early ICC,
that is, solitary tumor.
The retrospective nature of this study contributes to its major
limitation, possibility of selection bias, missing data, and
problems of treatment heterogeneity throughout the years could
not be completely evaded. On the hand, the effect of adjuvant
chemotherapy, which could potentially influence survival
outcome, was not investigated in the current study. Our series
included consecutive patients for analyses; hence the chance of
selection bias was minimized. A single-center series also limits
interobserver variability and treatment heterogeneity in terms of
perioperative management and operative techniques. While it
deems neither practical nor ethical to perform a prospective
randomized trial on the effective margin width, this retrospective
series of reasonable sample size serves to shed some light on the
surgical approach of patients with ICC.
5. Conclusion
ICC is an uncommon primary liver malignancy associated with
poor prognosis even operation can be done with curative intent.
Table 3






OT duration 485 (130–1305) 487.5 (375–954) 0.22
Major resection 66 (74.2%) 7 (87.5%) 0.682
Additional procedures 17 (89.5%) 2 (10.5%) 1
Size of primary tumor, cm 6 (1.5–17) 6.5 (3.5–9) 0.948
Differentiation 0.909
Well differentiated 7 (7.9%) 1 (12.5%)
Moderately differentiated 39 (43.8%) 4 (50%)
Poorly differentiated 24 (27%) 2 (25%)
Not available 19 (21.3%) 1 (12.5%)
Macrovascular invasion, yes (%) 11 (12.4%) 1 (12.5%) 1
Microvascular invasion, yes (%) 46 (51.7%) 4 (50%) 1
Node positivity 13 (14.6%) 1 (12.5%) 1
TNM staging (7th edition) 0.77
I 32 (36%) 3 (37.5%)
II 21 (23.6%) 3 (37.5%)
III 23 (25.8%) 1 (12.5%)
IV 13 (14.6%) 1 (12.5%)
TNM = tumor-node-metastasis.
Table 4




OR (95% CI) P
Age 0.68
Sex 0.24
Presence of comorbidities 0.363
Intraop blood loss 0.563
Bile duct resection 0.898
Vascular resection 0.079
Tumor size 0.026 NS
Postop complication 0.006 2.1 (1.21–3.62) 0.008
Multifocality <0.001 NS




II 0.003 2.59 (1.36–4.92) 0.004
III <0.001 3.8 (1.89–7.65) <0.001
IV <0.001 7.07 (2.8–117.86) <0.001
CI= confidence interval, NS= not significant, OR= odds ratio, UICC7= Union for International Cancer
Control, 7th edition.
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Figure 2. Discriminant analysis for margin width cut-off value for disease-free survival.
Table 5
Univariate and multivariate analyses of various factors against
overall survival.
Overall survival
Factors Univariable, P Multivariable, P [OR (95% CI)]
Age 0.861
Sex 0.384
Presence of comorbidities 0.501
Intraop blood loss 0.014
Bile duct resection 0.502
Vascular resection 0.218
Tumor size 0.101
Postop complication <0.001 <0.001 [2.87 (1.649–4.994)]
Multifocality <0.001
Width of resection margin 0.014
R0 or R1 resection 0.139
UICC7
I <0.001 <0.001
II 0.044 0.023 [2.198 (1.117–4.325)]
III <0.001 0.001 [3.476 (1.66–7.278)]
IV <0.001 <0.001 [6.59 (2.606–16.666)]
CI= confidence interval, OR= odds ratio, UICC7= Union for International Cancer Control, 7th edition.
Table 6
Factors associated with overall survival (subgroup analysis of
patients with solitary ICC).
Overall survival
Factors Univariable, P Multivariable, P [OR (95% CI)]
Age 0.562
Sex 0.411
Presence of comorbidities 0.392
Intraop blood loss 0.012
Bile duct resection 0.958
Vascular resection 0.13
Tumor size 0.247
Postop complication <0.001 0.002 [5.603 (1.929–16.278)]
Multifocality –
Width of resection margin 0.009 0.048 [0.577 (0.334–0.996)]
R0 or R1 resection 0.065
UICC7
I 0.004 0.039
II 0.041 0.035 [2.053 (1.05–4.014)]
III 0.181 0.558 [1.555 (0.355–6.816)]
IV <0.001 0.011 [4.131 (1.388–12.301)]
CI = confidence interval, ICC = intrahepatic cholangiocarcinoma, OR = odds ratio, UICC7 = Union for
International Cancer Control, 7th edition.
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Aggressive operative approach to obtain resection margin at least
1cm can improve patients’ survival outcomes.
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